Quick Answer
Melatonin Stress Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: 7 7 8 Despite a robust mechanistic basis, the existing clinical evidence regarding melatonin’s cardiovascular efficacy is fragmented and inconsistent.
Key Takeaways
- 017 7 8 Despite a robust mechanistic basis, the existing clinical evidence regarding melatonin’s cardiovascular efficacy is fragmented and inconsistent. [Ang Song Peng (2026)]
- 02We stratified data by distinct clinical settings, including perioperative cardiac surgery, acute myocardial infarction (AMI), and heart failure with reduced ejection fraction (HFrEF). [Ang Song Peng (2026)]
- 03Background pharmacotherapy was largely uniform within CABG and HF cohorts, with the majority of patients receiving guideline-directed medical therapy including beta-blockers, statins, renin-angiotensin system inhibitors, and antiplatelet agents. [Ang Song Peng (2026)]
- 041 2 3 4 5 6 6 Cardiovascular disease remains the predominant driver of global mortality and morbidity worldwide, with acute coronary syndromes, heart failure, and post-surgical cardiac dysfunction representing major sources of preventable death and disability. [Ang Song Peng (2026)]
The current Migaku evidence database contains 2 reusable source documents for Melatonin Stress Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- 7 7 8 Despite a robust mechanistic basis, the existing clinical evidence regarding melatonin’s cardiovascular efficacy is fragmented and inconsistent. [Ang Song Peng (2026); evidence level 1]
- We stratified data by distinct clinical settings, including perioperative cardiac surgery, acute myocardial infarction (AMI), and heart failure with reduced ejection fraction (HFrEF). [Ang Song Peng (2026); evidence level 1]
- Background pharmacotherapy was largely uniform within CABG and HF cohorts, with the majority of patients receiving guideline-directed medical therapy including beta-blockers, statins, renin-angiotensin system inhibitors, and antiplatelet agents. [Ang Song Peng (2026); evidence level 1]
- 1 2 3 4 5 6 6 Cardiovascular disease remains the predominant driver of global mortality and morbidity worldwide, with acute coronary syndromes, heart failure, and post-surgical cardiac dysfunction representing major sources of preventable death and disability. [Ang Song Peng (2026); evidence level 1]
- Although reperfusion therapies have improved outcomes, their narrow therapeutic window and limited availability leave many patients without effective treatment, highlighting the need for effective neuroprotective strategies capable of targeting multiple interconnected pathways. [Ortiz-Martínez G (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources